LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR? Activation.

ABSTRACT: RATIONALE:Arterial remodeling-a hallmark of many cardiovascular pathologies including pulmonary arterial hypertension (PAH)-is regulated by TGF?1 (transforming growth factor-?1)-TGF? receptors and the antagonistic, vasoprotective BMPR2 (bone morphogenetic protein receptor 2)-PPAR? (peroxisome proliferator-activated receptor-?) axis. However, it is unclear which factors drive detrimental TGF?1 pathways in the hypertensive pulmonary vasculature. OBJECTIVE:We hypothesized that LRP1 (low-density lipoprotein receptor-related protein 1) expression is decreased in PAH, leading to enhancement (disinhibition) of TGF?1 signals and that the PPAR? agonist pioglitazone can restore vascular homeostasis and prevent PAH resulting from LRP1 deletion in vascular smooth muscle cells (SMCs). METHODS AND RESULTS:Targeted deletion of LRP1 in vascular SMC (smLRP1-/-) in mice disinhibited TGF?1-CTGF (connective tissue growth factor) signaling, leading to spontaneous PAH and distal pulmonary arterial muscularization as assessed by closed-chest cardiac catheterization and anti-?SMA staining. Pioglitazone inhibited the canonical TGF?1-CTGF axis in human pulmonary artery SMC and smLRP1-/- main pulmonary artery (CTGF and NOX4) and reversed PAH in smLRP1-/- mice. TGF?1 boosted pSmad3 in PASMC from smLRP1-/- mice versus controls. Pioglitazone-activated PPAR? binds to Smad3 in human pulmonary artery SMC (coimmunoprecipitation), thereby blocking its phosphorylation and overriding LRP1 deficiency. Finally, mRNA and protein expression of LRP1 was decreased in pulmonary plexiform lesions of patients with end-stage idiopathic PAH (laser capture microdissection, qPCR, and immunohistochemistry). Downregulation of LRP1 protein was also demonstrated in explanted PASMC from patients with PAH and accompanied by enhanced TGF?1-pSmad3-CTGF signaling and increased TGF?1-induced PASMC proliferation that was prevented by pioglitazone. CONCLUSIONS:Here, we identify LRP1 as an integrator of TGF?1-mediated mechanisms that regulate vascular remodeling in mice and clinical PAH and PPAR? as a therapeutic target that controls canonical TGF?1 pathways. Hence, pharmacologic PPAR? activation represents a promising new therapy for patients with PAH who lack the vasoprotective LRP1 in vascular SMC.

SUBMITTER: Calvier L 

PROVIDER: S-EPMC6554044 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature